CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2018--
Seres
Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will
present at the 36th Annual J.P. Morgan Healthcare Conference
in San Francisco, CA on Thursday, January 11 at 8:30 a.m. PT.
A live audio webcast of the presentation and breakout question and
answer session will be available under the “Investors and Media” section
of Seres’ website. A replay of the presentation will become available
approximately one hour after the event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform
company developing a novel class of biological drugs that are designed
to treat disease by restoring the function of a dysbiotic microbiome,
where the natural state of bacterial diversity and function is
imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough
Therapy and Orphan Drug designations from the U.S. Food and Drug
Administration and is in Phase 3 development for multiply recurrent C.
difficile infection. Seres’ clinical candidate SER-287 has
successfully completed a Phase 1b study in patients with
mild-to-moderate Ulcerative Colitis. Seres is also developing SER-262,
the first ever synthetic microbiome therapeutic candidate, in a Phase 1b
study in patients with primary C. difficile infection. For more
information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180104005392/en/
Source: Seres Therapeutics, Inc.
IR or PR Contact:
Seres
Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor
Relations and Corporate Communications
ctanzi@serestherapeutics.com
